The METAvivor Research Program was established in 2009 with the singular goal of funding research to end death from metastatic breast cancer (MBC). The following list includes current and past grant recipients along with their progress reports.
Dr. Diana Cittelly
Assistant Professor, University of Colorado Anschutz Medical Campus
Targeting BDNF/TrkB in Brain Metastasis from Young Women with TNBC
Dr. Joshua Donaldson
Senior Medical Oncology Fellow, Johns Hopkins University
Resistance Mechanisms to Palbociclib in Hormone Positive Metastatic Breast Cancer
Dr. Michael Flister
Assistant Professor, Human and Molecular Genetics Center, Medical College of Wisconsin
Personalized Therapy for Curing Metastatic Breast Cancer
Dr. Andrei Goga
Professor, University of California, San Francisco
Targeting the MYC Pathway in Metastatic Breast Cancer
Dr. Cheryl Jorcyk
Professor, Director, Boise State University
High Impact Therapeutic for the Elimination of Breast Cancer Metastasis to Bone
Dr. Vivek Mittal
Professor of Cell and Developmental Biology, Weill Medical College of Cornell University
Targeting Epigenetic Regulator PRC2 as a Therapy for Established Metastasis
Dr. Partha Roy
Associate Professor of Bioengineering, University of Pittsburgh
Pharmacological Inhibition of Myocardin-Family Proteins as a Novel Strategy to Combat Metastatic Breast Cancer
Dr. Gina Sizemore
Assistant Professor, The Ohio State University
Targeting Novel Tumor-Stroma Interactions in Breast Cancer Brain Metastases
Dr. David Soto-Pantoja
Assistant Professor, Wake Forest School of Medicine Comprehensive Cancer Center
Anti-CD47 Immunotherapy as a Treatment for Metastatic Breast Cancer
Dr. Rebecca Watters
Research Assistant Professor, Department of Orthopaedic Surgery University of Pittsburgh
Discovery of Clinically Actionable Genes in Breast Cancer Bone Metastases
Dr. Paula Bos
Assistant Professor, Department of Pathology, Virginia Commonwealth University
Regulatory T Cell Promotion of Brain Metastatic Processes
Dr. Ian Corbin
Assistant Professor, Advanced Imaging Research Center, University of Texas Southwestern Medical Center
Lipoprotein Omega-3 Fatty Acid Nanoparticles: A Novel Treatment for Breast Cancer Liver Metastases
Dr. Kathleen Gallo
Professor of Physiology, Michigan State University
Deciphering and Targeting Signaling Nodes that Drive Metastatic Breast Cancer
Dr. Todd Giorgio
Vanderbilt University
Quantitative Characterization of Anti-Tumor Immune Response in Metastatic Breast Cancer Induced by Focused Ultrasound
Dr. Kathryn Schwertfeger
Associate Professor, Department of Lab Medicine and Patholody, Masonic Cancer Center For Immunology, University of Minnesota
Development of Immune-based Strategies to Enhance Therapeutic Targeting of Metastatic Breast Cancer
Dr. Patricia Sheean
Assistant Professor, School of Nursing, Loyola University Chicago
Is lean soft tissue (i.e., skeletal muscle) a potentially modifiable biomarker predictive of prognosis, treatment tolerance and quality of life in women with estrogen receptor negative metastatic breast cancer?
Dr. Brad St. Croix
Senior Associate Scientist, National Cancer Institute Center for Cancer Research
Improving Therapy for Metastatic Breast Cancer through Targeting of Tumor Stroma
Dr. J. Chuck Harrell (2015)
Assistant Professor, Department of Pathology, Virginia Commonwealth University
Genomic Dissection of Patient-Derived Xenograft Breast Cancer Liver Metastasis Models
Dr. Yibin Kang (2015)
Warner-Lambert/Park-Davis Professor of Molecular Biology, Princeton University
Development of a Humanized Mouse Model of Breast Cancer Liver Metastasis
Dr. Yibin Kang (2015)
Warner-Lambert/Parke-Davis Professor of Molecular Biology, Princeton University
Sensitizing Bone Metastasis to Chemotherapy and Radiotherapy by Targeting Jagged1-Mediated Tumor-Stromal Interactions
Dr. Bonnie King and Dr. Christopher Contag (2015)
Stanford University
Modeling Therapeutic Strategies for Breast Cancer Metastasis to Bone
Dr. Sendurai A. Mani (2015)
Associate Professor, University of Texas MD Anderson Cancer Center, Department of Translational Molecular Biology
Targeting Cancer Stem Cells to Treat Metastasis
Dr. Jitesh Pratap (2015)
Assistant Professor, Rush University Medical Center, Department of Anatomy & Cell Biology
Novel Regulatory Mechanisms of Cell Survival During Bone Metastasis of Breast Cancer
Dr. Tiffany Seagroves (2015)
Associate Professor of Pathology, University of Tennesee Health Science Center
Targeting Creatine Kinases to Inhibit Metastatic Breast Cancer
Dr. George Sgouros (2015)
Professor of Radiology, Oncology and Radiation Oncology, Johns Hopkins University, School of Medicine
A Pre-Clinical Model of anti-HER2/neu-Antibody Reactive Breast Cancer Metastases
Dr. Haifa Shen (2015)
Assistant Professor, Department of NanoMedicine, Houston Methodist Research Institute
Harnessing Vascular and Cellular Depots of Nanotherapeutics for the Treatment of Metastatic Breast Cancer
Dr. Kay-Uwe Wagner (2015)
Professor, Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center
Identification of Candidate Target Genes for Metastasis and Cancer Cell Dormancy in a Novel Triple-Negative Breast Cancer Model
Dr. Michael Wendt (2015)
Assistant Professor, Medicinal Chemistry and Molecular Pharmacology, Purdue University Center for Cancer Research
Targeting Growth-Factor Receptor Discordant Metastatic Breast Cancer
Dr. Elizabeth Yeh (2015)
Assistant Professor, Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina
Application of a Connexin 43 (Cx43) Targeted Agent for the Treatment of Metastatic Breast Cancer
Dr. Swarnali Acharyy a (2014)
Assistant Professor, Pathology and Cell Biology, Institute for Cancer Genetics, Columbia University
Reactivating anti-tumor granulocytic cells to provoke immune attack against breast cancer metastasis
Dr. Eran Andrecheck (2014)
Department of Physiology, Michigan State University
Identification of driver mutations that regulate metastasis
Dr. Balamurugan Kuppusamy (2014)
Staff Scientist, NCI/NIH
Inflammatory Breast Cancer: Role of the CEBPD-FBXW7 Signaling Pathway
Dr. William Schiemann (2014)
Professor and Co-Director Breast Cancer Program, Case Comprehensive Cancer Center, Case Western Reserve University
Implementing a Forward Genetic Screen to Identify Novel Proto-Oncogenes Operant in Overcoming Metastatic Dormancy
Dr. Sofia Merajver (2013)
University of Michigan Comprehensive Cancer Center, Ann Arbor, MI
Engineering cancer metastases platforms for precise medicine
Dr. Douglas Hurst (2013)
University of Alabama at Birmingham, Alabama
Improving oncolytic herpes simplex virus for metastatic breast cancer
Dr. David Lum (2013)
Oklahoma Medical Research Foundation
Validation of patient-derived breast tumor grafts as predictors of tumor evolution and drug resistance
Dr. Dihua Yu (2013)
The University of Texas MD Anderson Cancer Center,Houston, TX
Identification and Targeting of Kinases Involved in Breast Cancer Brain Metastasis
Dr. Candece L. Gladson, M.D. (2012)
The Nancy and William E. Harris Endowed Chair and Professor of Molecular Medicine, Cleveland Clinic
FIP200 promotes survival through autophagy of metastatic breast cancer in the brain
Dr. Heide L. Ford, Ph.D. (2012)
Associate Professor, Dept. of Obstetrics & Gynecology, Division of Basic Reproductive Sciences, University of Colorado School of Medicine
Understanding the Role of miR106b-25 in Breast Cancer Associated Metastasis: A potential new metastasis therapy?
Rahul Jandial, MD, PhD (2012)
Neurosurgeon and researcher at City of Hope Comprehensive Cancer Treatment Center in California
Disrupting metabolic adaptations in breast-to-brain metastases
Dr. Alana Welm (2011)
Oklahoma Medical Research Foundation
Test the value of tumorgrafts in predicting response to therapy.
Dr. Andrea M. Mastro (2011)
The Pennsylvania State University, University Park, PA
Dormancy or growth? A three dimensional in vitro system to study breast cancer metastases in bone
Dr. Danny Welch (2010)
Associate Director of Basic Science, University of Kansas Cancer Center
KISS1 prevents seeded cancer cells from growing into full blown metastases
